Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB1676 : JHOM-1  update : 2024/09/30
CommentHuman cell line derived from ovarian mucinous adenocarcinoma. Application consideration
Comment from the depositor
Terms and conditionsA prior written permission of the approver(Depositor) is necessary for any kind of use including academic use and for-profit use.
Remarks
approver's address
×
English
Address
Contact Us
cellbank.brc@riken.jp
RIKEN, BioResource Research Center
Cell Engineering Division
Dr.ISHIKAWA Hiroshi (Cell Bank)
Fax. +81-29-836-9130
Order Form Order Form(C-0005.pdf)   Approval Form(C-0006.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor Ishikawa, Hiroshi
Originator Ishikawa, H. & Yasuda, M.
Year of deposit 2000
Animal _human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Female
Age at sampling 88 years
Tissue ovary
Disease name mucinous adenocarcinoma
Classification cancer
Year of origin 1997
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_4644
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium DMEM/HamF12 + 10% FBS + 0.1mM NEAA
Antibiotics Free
Passage method 0.25% Trypsin
Culture information Passage ratio 1 : 6-8 split
SC frequency Subculture : 1-2 times/week, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma/Acholeplasma (-)
Isozyme LD, NP
STR(human) OK
Images
deposit info
lot info
Reference information Reference 0
User's Publication 7


To topTop
Reference

To topTop
User's Publication
21801  Takaki EO, Kiyono K, Obuchi Y, Yamauchi T, Watanabe T, Matsumoto H, Karimine M, Kuniyoshi Y, Nishikori S, Yokoyama F, Nishimori H, Nabeshima H, Nakamura K.  A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors.  Clin Cancer Res  2024    PubMed ID: 38864850   DOI: 10.1158/1078-0432.CCR-24-0096
20604  Kobayashi Y, Takeda T, Kunitomi H, Chiwaki F, Komatsu M, Nagai S, Nogami Y, Tsuji K, Masuda K, Ogiwara H, Sasaki H, Banno K, Aoki D.  Response Predictive Markers and Synergistic Agents for Drug Repositioning of Statins in Ovarian Cancer.  Pharmaceuticals (Basel)  2022  15(2)  PubMed ID: 35215239   DOI: 10.3390/ph15020124
13459  Inaba K, Oda K, Aoki K, Sone K, Ikeda Y, Miyasaka A, Kashiyama T, Fukuda T, Makii C, Arimoto T, Wada-Hiraike O, Kawana K, Yano T, Osuga Y, Fujii T.  Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging  Oncotarget  2016  7(20):29577-91.  PubMed ID: 27102436   DOI: 10.18632/oncotarget.8807
14315  Davis SJ, Sheppard KE, Anglesio MS, George J, Traficante N, Fereday S, Intermaggio MP, Menon U, Gentry-Maharaj A, Lubinski J, Gronwald J, Pearce CL, Pike MC, Wu A, Kommoss S, Pfisterer J, du Bois A, Hilpert F, Ramus SJ, Bowtell DD, Huntsman DG, Pearson RB, Simpson KJ, Campbell IG, Gorringe KL.  Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition  Mol Cancer Ther  2015  14(6):1495-503  PubMed ID: 25852062   DOI: 10.1158/1535-7163.MCT-15-0039
15031  Takaya A, Peng WX, Ishino K, Kudo M, Yamamoto T, Wada R, Takeshita T, Naito Z.  Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma  Int J Oncol  2015  46(4):1573-81  PubMed ID: 25633807   DOI: 10.3892/ijo.2015.2858
16003  Kudoh A, Oishi T, Itamochi H, Sato S, Naniwa J, Sato S, Shimada M, Kigawa J, Harada T.  Dual inhibition of phosphatidylinositol 3'-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary  Int J Gynecol Cancer  2014  24(3):444-53  PubMed ID: 24552895   DOI: 10.1097/IGC.0000000000000091
9669  Ikue Nakayama, Masahiko Shibazaki, Akiko Yashima-Abo, Fumiharu Miura, Toru Sugiyama, Tomoyuki Masuda, Chihaya Maesawa  Loss of HOXD10 Expression Induced by Upregulation of miR-10b Accelerates the Migration and Invasion Activities of Ovarian Cancer Cells  Int J Oncol  2013  43(1):63-71  PubMed ID: 23670532   DOI: 10.3892/ijo.2013.1935


Back Back Return Top Page